1. Home
  2. CTXR vs SCLX Comparison

CTXR vs SCLX Comparison

Compare CTXR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

SELL

Current Price

$0.51

Market Cap

13.4M

Sector

Health Care

ML Signal

SELL

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$0.57

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTXR
SCLX
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
12.0M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
CTXR
SCLX
Price
$0.51
$0.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 253.3K
73.1K
Earning Date
12-22-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 43.38
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $30,253,000.00
Revenue This Year
N/A
$118.16
Revenue Next Year
$104.18
$186.31
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.37
$0.54
52 Week High
$1.54
$23.03

Technical Indicators

Market Signals
Indicator
CTXR
SCLX
Relative Strength Index (RSI) 48.05 8.42
Support Level $0.47 N/A
Resistance Level $0.63 $7.77
Average True Range (ATR) 0.06 0.17
MACD -0.00 -0.04
Stochastic Oscillator 22.42 2.80

Price Performance

Historical Comparison
CTXR
SCLX

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: